News

Wednesday, 14 April, 2021 - I am honoured to join you at the plenary of the 64th session of the Commission on Narcotic Drugs. My statement today is the result of the virtual pre-CND multi-stakeholders consultation organized by UNODC HIV Section in close collaboration with the IAS - International AIDS Society, World Health Organization, UNAIDS and INPUD. For people who use drugs, COVID-19 has added to an already difficult situation marked by widespread violations of human rights, criminalization...

Friday, 29 January, 2021 (Geneva, Switzerland) - On 28 January 2021, US President Joseph R. Biden signed an executive order repealing the harmful U.S. Mexico City Policy, more commonly known as the global gag rule. President Biden lifted these restrictions by signing the “Memorandum on Protecting Women’s Health at Home and Abroad.” “IAS – the International AIDS Society - welcomes the end to the harmful global gag rule and urges the US administration to consider legislation preventing the ...

IAS – the International AIDS Society – mourns the passing of two world-leading HIV scientists, David Katzenstein, Professor of Medicine at Stanford University, and James Hakim, Professor of Medicine at the University of Zimbabwe College of Health Sciences, who died from COVID-19 related complications. “We send our deepest condolences to David’s and James’ families and loved ones at this difficult time,” said Adeeba Kamarulzaman, President of the IAS. “In the last few days, we have lost t...

Results of the Antibody Mediated Prevention (AMP) studies to be presented at the IAS HIV Research for Prevention (HIVR4P // Virtual) conference. Tuesday, 26 January, 2021 (Geneva, Switzerland) — IAS – the International AIDS Society – welcomes new results from two proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081- the AMP Studies) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections. Results of the stu...

Important advances in HIV prevention research were announced today at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), convened by IAS – the International AIDS Society. Highlights included findings from a pair of trials evaluating whether infusions with a broadly neutralizing antibody (bNAb) can prevent HIV acquisition and positive interim results from a study of long-acting injectable pre-exposure prophylaxis (PrEP) in women. Other announcements included promising data from...

It is my great honour to announce that Dr Birgit Poniatowski is the next Executive Director of IAS – the International AIDS Society. She assumes the role with immediate effect.

New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill (emtricitabine/tenofovir disoproxil fumarate) in a trial of women at increased risk of HIV acquisition.

Countering the COVID-19 infodemic requires not only facts, but also the coordinated and strategic advocacy for which those fighting HIV are renowned. Now more than ever, scientists need to counter lies and myths, and defend the integrity and independence of their enterprise. The emergence of the SARS-CoV-2 virus has not only led to the global COVID-19 pandemic, but also fueled an accompanying onslaught of misinformation. Some have promoted drugs such as hydroxychloroquine as cures for the disea...

Cori Vail has been elected as the ILF industry representative. Cori currently leads HIV Access Strategy & Impact efforts as part of Johnson & Johnson’s Global Public Health team. In this role, she is responsible for developing and executing insight-based strategies to accelerate adoption of transformational HIV innovation for underserved populations in resource-limited settings. Cori joined the Johnson & Johnson family of companies in 2003 and held numerous roles across engineering,...

It is with sadness and much gratitude that, on behalf of IAS - the International AIDS Society - Governing Council, I am letting you know that IAS Executive Director Kevin Osborne has announced his departure from the organization. After close to five successful years at the IAS, first as Director of HIV Programmes and Advocacy, and then as Executive Director, Kevin will depart at the end of September 2020 to join his partner abroad. With Kevin at the helm, the organization has benefited from his...